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Abstract
Background—During long-term anticoagulation in atrial fibrillation, temporary interruptions
(TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been
well studied. We sought to determine reasons for TI, the characteristics of patients undergoing TI,
and the relationship between anticoagulant and outcomes among patients with TI.
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Methods and Results—In the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition
Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation (ROCKET AF), a randomized, double-blind, double-dummy study of rivaroxaban and
warfarin in nonvalvular atrial fibrillation, baseline characteristics, management, and outcomes,
including stroke, non–central nervous system systemic embolism, death, myocardial infarction,
and bleeding, were reported in participants who experienced TI (3–30 days) for any reason. The
at-risk period for outcomes associated with TI was from TI start to 30 days after resumption of
study drug. In 14 236 participants who received at least 1 dose of study drug, 4692 (33%)
experienced TI. Participants with TI were similar to the overall ROCKET AF population in regard
to baseline clinical characteristics. Only 6% (n=483) of TI incidences involved bridging therapy.
Stroke/systemic embolism rates during the at-risk period were similar in rivaroxaban-treated and
warfarin-treated participants (0.30% versus 0.41% per 30 days; hazard ratio [confidence
interval]=0.74 [0.36–1.50]; P=0.40). Risk of major bleeding during the at-risk period was also
similar in rivaroxaban-treated and warfarin-treated participants (0.99% versus 0.79% per 30 days;
hazard ratio [confidence interval]=1.26 [0.80–2.00]; P=0.32).
Conclusions—TI of oral anticoagulation is common and is associated with substantial stroke
risks and bleeding risks that were similar among patients treated with rivaroxaban or warfarin.
Further investigation is needed to determine the optimal management strategy in patients with
atrial fibrillation requiring TI of anticoagulation.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier:
NCT00403767.
Keywords
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anticoagulation; atrial fibrillation; stroke
In patients with atrial fibrillation (AF), anticoagulation reduces the risk of stroke and
embolic events and improves survival.1–4 Annually, nearly 250 000 AF patients in the
United States alone require temporary interruption (TI) of anticoagulation for invasive
procedures,5 acute illness, or bleeding events. Bridging therapy may or may not be pursued
on the basis of clinical evaluation and physician perception of thrombotic risk versus
bleeding risk.5,6 Although several clinical studies have examined the characteristics of
patients with TI of anticoagulant therapy and the potential need for bridging therapy,7–10
there are limited data regarding downstream thrombotic and bleeding outcomes in these
populations,11 and even less is known about TI of novel oral anticoagulants in
periprocedural settings.12
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The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET
AF) demonstrated that rivaroxaban was noninferior to warfarin in the prevention of stroke
and systemic thromboembolic events in moderate- to high-risk participants with nonvalvular
AF.3 During the course of the trial, many participants required TI of anticoagulant
medication. The objectives of the present analyses are to characterize those participants who
required TI of oral anticoagulation, to examine reasons for TI, to describe patterns of
bridging therapy, and to evaluate outcomes associated with rivaroxaban and warfarin.

Methods
Patient Population
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The design, methods, and primary results of the ROCKET AF trial have been described
previously.13 Briefly, ROCKET AF was a randomized, double-blind, double-dummy trial
comparing fixed-dose rivaroxaban (20 mg daily or 15 mg daily in participants with a creatinine clearance of 30–49 mL/min) versus dose-adjusted warfarin (maintaining an
international normalized ratio in the therapeutic range [2.0–3.0]) in participants with
nonvalvular AF and moderate to high risk for stroke. The principal efficacy outcome was the
occurrence of any stroke or non–central nervous system (CNS) systemic embolism. The
principal safety outcome was the composite of International Society on Thrombosis and
Hemostasis major bleeding and nonmajor clinically relevant (NMCR) bleeding.14
The ROCKET AF trial was supported by research grants from Johnson & Johnson
Pharmaceutical Research and Development (Raritan, NJ) and Bayer Healthcare AG
(Leverkusen, Germany). The Duke Clinical Research Institute (Durham, NC) coordinated
the trial and performed the statistical analyses for this article independent of the sponsors.
All appropriate national regulatory authorities and ethics committees at participating centers
approved the study. An international executive committee designed the study and takes
responsibility for the accuracy and completeness of the analyses.
For baseline summaries and occurrence of TI, all participants in the safety on-treatment
population, defined as those who were randomized and received at least 1 dose of study
drug, were included. All other analyses included the subset of patients with 1 or more TIs.
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Outcomes and Definitions
TI of oral anticoagulation was defined as cessation of study drug for ≥ 3 days, due to any
cause without transition to an open-label anticoagulant, with resumption of study drug
within 30 days. The at-risk period for outcomes associated with TI was defined as the
duration of the TI plus 30 days after the resumption of study drug. This period was chosen in
efforts to evaluate the outcomes associated with TI and the time period after resumption of
study drug. This is also the time frame recommended by a task force consensus document
derived from available data.15 In cases in which study drug was resumed and stopped again
within 30 days, the first at-risk period extended only to the day before the new interruption.
Information on the type of procedure, date of procedure, and details concerning study drug
interruption were captured in electronic case report form for the ROCKET AF trial. Invasive
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procedures were defined as any percutaneous or surgical procedure that would typically
require cessation of warfarin. These included coronary angiography, percutaneous coronary
intervention, peripheral vascular intervention, surgery, endoscopy, electrophysiology
procedures, endoscopy/colonoscopy, and tissue biopsies as well as major dental procedures.
Stroke was defined as a sudden, focal neurological deficit resulting from a presumed
cerebrovascular cause that is not reversible within 24 hours and not due to a readily
identifiable cause, such as a tumor or seizure. Non-CNS systemic embolism was defined as
abrupt vascular insufficiency associated with clinical or radiological evidence of arterial
occlusion in the absence of other likely mechanisms (eg, trauma, atherosclerosis, or
instrumentation). Myocardial infarction was defined by clinical symptoms consistent with
myocardial infarction and cardiac biomarker elevation (troponin I or T, creatine kinase–
muscle and brain subunit) greater than the upper limit of normal, the development of new
pathological Q waves in ≥2 contiguous ECG leads, or confirmed by autopsy.
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Major bleeding was defined as clinically overt bleeding associated with any of the
following: fatal outcome, involving a critical site (ie, intracranial, intraspinal, intraocular,
pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal), or
clinically overt bleeding associated with a fall in hemoglobin concentration of ≥2 g/dL or
leading to transfusion of ≥2 U of packed red blood cells or whole blood.14 NMCR bleeding
was defined as overt bleeding not meeting the criteria for major bleeding but associated with
medical intervention, unscheduled contact with a physician (visit or telephone call),
temporary (ie, by delaying the next study drug administration) cessation of study drug, pain,
or impairment of daily activities.14 All other overt bleeding episodes not meeting the criteria
for major or NMCR bleeding are classified as minor bleeding. All primary and secondary
outcome events were adjudicated by a blinded, independent multispecialty clinical end point
committee as part of the ROCKET AF trial.
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In the ROCKET AF trial protocol, investigators were given the option to utilize bridging
therapy in appropriate participants at intermediate to high risk for thromboembolic events
(considered as those with >2 risk factors for stroke) that experienced TI. Both use of
bridging therapy and selection of medications were left to the investigators’ discretion.
Information on the use of bridging therapy was collected through the ROCKET AF trial
electronic case report form by matching the dates of medication use forms (specifically for
heparins and other parental or subcutaneous anticoagulants) to TI dates.
Statistical Analyses
Baseline characteristics are summarized according to TI status, randomized treatment, and
use of bridging therapy. Continuous variables are shown as median (25th, 75th percentile),
and categorical variables are shown as frequency (percentage). Among participants with at
least 1 TI, characteristics of participants who received bridging therapy at least once were
compared with those of participants who did not with the use of Wilcoxon rank sum tests or
Pearson 2 tests as appropriate. Because early study drug discontinuations resulted in a high
level of early censoring, rates of temporary interruption at different times were estimated by
cumulative incidence functions that treat early permanent drug discontinuation and death as
competing risks to TI. Cumulative incidence curves were compared with the Gray test.16
Circulation. Author manuscript; available in PMC 2014 November 06.
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Outcomes occurring during TI risk periods are summarized by randomized treatment and by
bridging therapy as number of events and event rates per 30 days. Association of
randomized treatment with risk of outcome was assessed with Cox proportional hazards
models in which each TI was an observation and that used robust sandwich variance
estimators to account for correlation of multiple TIs within participants. Each participant
could meet each end point only once; when a participant met an end point, subsequent TIs
for that participant were not included in that model. Risk relationships are expressed as
hazard ratios with 95% confidence intervals. Relationships between bridging therapy and
risk of outcomes were not formally tested because of the very small number of events within
the small subgroup of bridged TIs and complexities caused by the occurrence of both
bridged and unbridged TIs in the same patients.
Sensitivity Analyses
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Given concern for possible confounding for TIs associated with an adverse bleeding event,
resulting in higher reported resultant bleeding risks, sensitivity analyses were performed to
evaluate risks of bleeding in the subset of TI participants, excluding those TIs caused by an
adverse bleeding event. Additional sensitivity analyses were also performed to evaluate risk
relationships in the surgical/invasive procedure TI population alone. All analyses were
performed with the use of SAS software version 9.2 (SAS Institute Inc, Cary, NC). A 2sided P value <0.05 was considered statistically significant.

Results
Temporary Interruption Population
A total of 4692 participants in ROCKET AF (33% of 14 236 who were randomized and
received study drug) experienced 7555 episodes of TI, of which 3393 occurred in
participants treated with rivaroxaban and 4162 in participants treated with warfarin.
Warfarin-treated participants experienced higher rates of TI over a 24-month follow-up
period compared with rivaroxoban-treated participants (Figure 1; P<0.0001). The median
duration of TI was 5 (4, 9) days. Among those with TI, 63% had 1 TI, 24% had 2 episodes,
and 13% had ≥3 episodes of TI.
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Baseline patient characteristics are reported in Table 1. In general, participants who
experienced TI were similar to the overall population of participants, with comparable
median age, creatinine clearance, time of exposure to treatment, mean CHADS2 scores, and
rates of hypertension, diabetes mellitus, congestive heart failure, prior stroke, prior
myocardial infarction, and prior vitamin K antagonist use. Participants with TI receiving
rivaroxaban were similar to those receiving warfarin for each of these characteristics as well.
TI Characteristics
The reasons for TI in the ROCKET AF trial are shown in Table 2. Forty percent experienced
TI for a surgical or invasive procedure, 25% of participants had TI for an adverse event
unrelated to bleeding, and 13% had TI for an adverse bleeding event. The remaining (12%)
were attributed to subject error (majority), site error, and logistic difficulties. These results
were similar when only the first episode of TI was considered.
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Among TIs for a surgical or invasive procedure, the interruption was prompted by a variety
of invasive procedures (Figure 2). The most common causes of TI were colonoscopy or
gastrointestinal endoscopic procedures (17%) and dental work (17%). Various abdominal,
thoracic, and orthopedic surgeries (13%), electrophysiology procedures (9%), and
dermatologic procedures (11%) also contributed significantly, whereas angiography,
percutaneous coronary intervention, peripheral intervention (4%), and eye surgery (8%)
contributed to a lesser degree. Eleven percent of TIs were due to surgical/invasive
procedures in which details of the procedure are unknown. There were no meaningful
differences in the frequency of different types of invasive procedures that prompted TI
between rivaroxaban- and warfarin-treated patients (Figure I in the online-only Data
Supplement).
Bridging Patterns and Patient Characteristics
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Only 9% (n=431) of patients with TI during the ROCKET AF trial received bridging
therapy during at least 1 TI. Most patients with TI who received bridging therapy were
treated with low-molecular-weight heparin (98.6%), whereas the remaining patients were
treated with fondaparinux (1.4%). The median duration of bridging therapy was 6 (4, 9) days
(Table 2). Patient characteristics according to the presence or absence of bridging therapy
are summarized in Table 3. Bridged and unbridged participants had similar rates of
hypertension, diabetes mellitus, prior stroke, and congestive heart failure. Participants who
received bridging therapy were older, were less commonly on prior aspirin therapy, more
commonly had prior exposure to vitamin K antagonists, and had slightly higher mean
CHADS2 risk scores (3.52 versus 3.40; P=0.009). These results were similar when only the
first episode of TI was considered.
Outcomes in TI
By Treatment Arm—Outcomes according to randomized treatment assignment are shown
in Table 4. The risk of stroke or non-CNS systemic embolism during any at-risk period of TI
was not significantly different in rivaroxaban-treated patients versus warfarin-treated
patients. Risks of myocardial infarction and death were also not different between treatment
groups. Similarly, risks of major bleeding and the composite NMCR bleeding and major
bleeding were not different in those receiving rivaroxaban versus warfarin.
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In the Subset of TI Patients Undergoing a Surgical/ Invasive Procedure—More
than 40% of TI patients (2130) experienced TI for a surgical or invasive procedure, and their
outcomes are shown in Table 5. The risk of stroke or non-CNS systemic embolism during
any at-risk period of TI for a surgical or invasive procedure was not significantly different in
rivaroxaban-treated patients versus warfarin-treated patients. Risks of myocardial infarction
and death were also not different between treatment groups. Risks of major bleeding and the
composite NMCR bleeding and major bleeding were not different in those receiving
rivaroxaban versus warfarin in this subset of TIs. Results for a sensitivity analysis evaluating
all TIs excluding those specifically for a bleeding event showed no differences between
treatment arms, consistent with the aforementioned results (Table I in the online-only Data
Supplement).
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By Timing of Study Drug Discontinuation—The occurrence of bleeding outcomes in
relation to cessation of study drug before an invasive procedure is shown in Table 6. For the
majority of TIs due to invasive procedures (90%; 2299/2547), study drug was stopped ≥3
days before the procedure. The vast majority of bleeding events also occurred in this group
(88%; 61/69), although the distribution and frequency were similar to those in the other
groups.
By Use of Bridging Therapy—Outcomes according to use of bridging therapy are
depicted in Table 7. Stroke/systemic embolism rates during TIs with bridging compared
with those without bridging were not different. Rates of major bleeding were similar
between bridged and nonbridged TIs, whereas rates of major/NMCR bleeding appeared
numerically higher in patients receiving bridging therapy (4.83% versus 3.02%).

Discussion
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This analysis of the ROCKET AF trial population represents one of the largest TI cohorts
ever studied, with nearly 4700 participants experiencing >7000 TI and 431 participants
receiving bridging therapy. The majority of TI episodes in ROCKET AF were due to
invasive procedures (40%); however, a considerable proportion of TIs were also secondary
to bleeding-related events and patient factors. Our report on this broad population is the first
of its kind for novel oral anticoagulant therapy. Patterns of TI were due to a variety of minor
and major invasive medical procedures, which are similar to those in prior observational
studies.9,11 Duration of TI was often short (5 days) in our population, and bridging therapy
with enoxaparin or fondaparinux was used in only 6% of TIs. TI was associated with a 30day stroke/systemic embolism rate of 0.36% and major bleeding rate of 0.88%, which is
notable compared with the overall rates in the ROCKET trial of 2.2%/y and 3.5%/y,
respectively.3 However, the risks of stroke/systemic embolism and clinically relevant
bleeding associated with TI were similar in rivaroxaban- and warfarin-treated participants.
Characteristics of TI
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Participants treated with warfarin had higher rates of TI compared with those on rivaroxaban
in our analyses. Although clinicians might surmise that the higher rate of TI in warfarin
patients would be due to a greater rate of adverse events or procedures, risks of adverse
events and surgical/invasive procedures were similar among participants in both treatment
groups experiencing TI. Participants and investigators were blinded and a double dummy
procedure was in place, and therefore bias from knowledge of working with warfarin was
mostly eliminated. There may have been incidences of pseudo-unblinding that were not
documented, possibly by performing coagulation measures as part of a routine screening
before surgical/invasive procedures or during adverse events. This may account for part of
the discrepancy seen between warfarin and rivaroxaban, which is admittedly difficult to
explain in this context.
Stroke With TI
The 30-day rate of stroke or non-CNS embolism in our study population was 0.36%, which
is notable compared with the overall stroke/systemic embolism rate in the ROCKET AF trial
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of 2.2%/y.3 The observed embolic event rates are high if prorated over a 1-year period but
are consistent with findings in other populations in which there is TI of anticoagulant
therapy.8 Possible factors that explain such higher-than-expected rates of embolic events
include a prothrombotic perioperative milieu among patients having TI for surgery and a
prothrombotic milieu associated with TI due to bleeding. In addition, patients enrolled in the
ROCKET AF trial were considered high risk, and the embolic event rate during TI likely
also reflects their intrinsic susceptibility to such outcomes. Our finding neither supports nor
refutes a “rebound effect” with TI of either anticoagulant, especially given the short period
(median=5 days) of anticoagulant interruption, and the clinical evidence for this
phenomenon remains tenuous.15 Although differences were seen in stroke rates in the endof-study analyses of the ROCKET AF trial, we believe that this was due to the unbalanced
(worse in rivaroxaban patients) lack of continuous therapeutic anticoagulation at the end of
the study period; this has been described elsewhere.17 However, the results compare
favorably with a recently published large meta-analysis of patients on vitamin K antagonists
receiving bridging or no bridging therapy in the periprocedural setting.8 That study
described an acute thromboembolism event rate of ≈ 1.0% and a rate of periprocedural
stroke/systemic embolism events of ≈ 1%.8 In addition, the risk of stroke/systemic
embolism events compares favorably to the only other published database of periprocedural
outcomes with the novel oral anticoagulant dabigatran in a lower-risk population as part of
the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, with a
30-day acute thromboembolism event rate of 1%, with ≈ 17% of patients receiving heparin
bridging therapy.12 In our study, there was no detectable difference in the risk of stroke and
systemic embolism for participants treated with rivaroxaban versus warfarin undergoing TI,
consistent with the overall trial results.3
Bleeding With TI
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Bleeding rates in those experiencing TI can be significant.9,18,19 The aforementioned large
meta-analysis described a 30-day major bleeding rate of ≈ 4% in warfarin-treated patients in
periprocedural settings, with bridging therapy conferring a >3-fold increase risk of major
bleeding.8 In our study, participants who underwent TI for invasive procedures had rates of
major bleeding and NMCR bleeding of ≈ 1% and 3% per 30 days, respectively, which were
similar between treatment groups. This finding was consistent with data from the main trial,
which showed that rates of major and NMCR bleeding were similar (14.9% versus 14.5%
per year; P=0.44) between treatment groups.3 This is also consistent with periprocedural
data from the RE-LY trial, which showed major bleeding and minor bleeding rates of ≈ 4%
and ≈ 8%, respectively. Thus, our data in a high-risk population with AF on chronic
anticoagulation in periprocedural settings compare favorably with previous evidence for
postprocedural major bleeding rates with vitamin K antagonists and dabigatran.12
Patterns of Bridging Therapy
The use of bridging therapy was infrequent, at 6% of all TIs in the on-treatment safety
population despite the moderate-to high-risk nature of this group (mean CHADS2
score=3.4). This observation was similar to data from Garcia et al,11 showing that rates of
bridging were low (8.3%) in an observational cohort of chronically anticoagulated
participants with diverse indications. Current guidelines indicate that the thromboembolic
Circulation. Author manuscript; available in PMC 2014 November 06.
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risk of TI should be estimated and weighed against the estimated risk of perioperative
bleeding, and then bridging therapy should be utilized predominantly in the individuals at
highest risk of thromboembolism.5 A possible explanation for the pattern of therapy seen in
our analyses may be due to the blinding of participants and investigators in the ROCKET
AF trial. Often clinicians are hesitant to introduce a second anticoagulant therapy to a patient
experiencing TI if they are unsure of the current status of anticoagulation (in this case,
because they are blinded to therapy). This may have led to the very low rates of bridging
therapy utilization observed in this study. Participants were predominantly bridged with
low-molecular-weight heparin in this analysis, consistent with current guideline
recommendations.5
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The rates of major bleeding were ≈ 1% among TIs with bridging therapy, whereas only 1
stroke or systemic embolism occurred in our small group. This is consistent with recent
meta-analyses data showing low rates of thromboembolism (<1%) and bleeding (≈4%) in
patients on chronic vitamin K antagonist therapy undergoing elective procedures with and
without heparin bridging.8 Significance testing was not performed because of the small
absolute number of events in the relatively small set of TIs that were bridged and because of
the confounding present between bridged and unbridged TIs in the same participants.
However, the data raise the question of whether the benefit of lower thrombotic events
might be mitigated by an increased risk of bleeding associated with bridging
anticoagulation. Current data available to answer this question are mixed,9,10,18 and there is
no clear consensus to the risks and potential benefits of bridging therapy. Although
published guidelines exist in regard to the management of novel oral anticoagulants in the
periprocedural setting,15 they are based primarily on expert opinion, with little evidence to
drive clinical management. Further work on this topic, including whether there is a role for
heparin bridging therapy in patients on rivaroxaban in periprocedural settings, is needed.
Limitations
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Our study has several limitations. First, it is a retrospective analysis of clinical trial data, and
thus there is likely selection bias in regard to patient patterns of TI and bridging therapy.
However, a particular strength of the analyses is that all participants and investigators were
blinded to treatment assignment. Thus, the majority of comparisons made in this study were
between the randomized treatment groups from the original trial, which should strengthen its
validity by mitigating intentional biases. We acknowledge that utilization of bridging
therapy was not randomized, and therefore any comparisons made between bridged and
unbridged TIs may be subject to multiple biases. Thus, we chose to limit these comparisons.
Although our study represents one of the largest populations of TI participants studied, with
a large number of temporary interruptions, the number of events compared between groups
is low. As a post hoc analysis, there was insufficient power to compare the TI subpopulation
with the overall ROCKET AF population and examine the effect of TIs on clinical
outcomes. In addition, because these are nonrandomized comparisons and because of the
low number of events, we did not pursue multivariable statistical modeling. In addition, we
did not have full and detailed data for the characteristics of these temporary interruptions,
including the urgency (eg, elective versus emergent) of the surgical or invasive procedures
leading to TI, as well as the relationship of study drug restart to the date of potential surgical
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or invasive procedures. Finally, for 11% of TIs due to surgical/invasive procedures, we did
not have details on type, indication, or duration of that procedure. Lacking these data limited
the depth of analyses that could be performed for the outcomes of TI.
Conclusions
In the ROCKET AF study, a large international population of participants with nonvalvular
AF, TI of oral anticoagulation occurred in ≈ 10% of patients per year, with only a minority
of patients (<10%) receiving bridging therapy. During the at-risk period associated with TIs,
we observed a 30-day stroke/systemic embolism rate of 0.4% and a major bleeding rate of
0.9%. The risks of thrombotic and bleeding complications were comparable between
rivaroxaban- and warfarin-treated participants experiencing TI. TI of oral anticoagulation
should be avoided to minimize adverse outcomes. Given the lack of randomized data in this
area, further research is necessary to determine the safest way to manage both warfarin and
novel anticoagulant medications, such as rivaroxaban, during TIs.
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The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin
K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation
(ROCKET AF) demonstrated that rivaroxaban was noninferior to warfarin in the
prevention of stroke and systemic thromboembolic events in moderate- to high-risk
participants with nonvalvular atrial fibrillation. During the course of the trial, many
participants required temporary interruption of anticoagulant medication for surgery,
invasive procedures, or adverse events. Our analysis provides one of the largest
experiences of patients undergoing temporary interruption of oral anticoagulation for
procedural and nonprocedural reasons and is one of the first to evaluate this clinical
scenario in patients treated with a novel oral anticoagulant. In this clinical trial setting,
the use of bridging anticoagulation was very low despite the high thrombotic risk of the
population. There was no difference in thrombotic or bleeding events during or after
temporary interruption in patients treated with rivaroxaban compared with patients
treated with warfarin. However, given the substantial thrombotic and bleeding risks
associated with temporary interruption of oral anticoagulation, it should be avoided if at
all possible.

NIH-PA Author Manuscript
Circulation. Author manuscript; available in PMC 2014 November 06.

Sherwood et al.

Page 13

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 1.

Cumulative incidence plot of time to first temporary interruption by treatment group,
showing the longitudinal analysis for time to first temporary interruption for warfarin- and
rivaroxaban-treated patients. Warfarin-treated patients were significantly more likely to
experience temporary interruption during follow-up.
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Figure 2.

Distribution of surgical/invasive procedures requiring temporary interruption, showing the
frequency of different types of surgical procedures that were listed as reasons for temporary
interruptions in the Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared
With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation (ROCKET AF). Abd indicates abdominal; Bx, biopsy; CABG, coronary artery
bypass graft; EP, electrophysiology; GI, gastrointestinal; Ortho, orthopedic; PCI,
percutaneous coronary intervention; and Thora, thoracic.
Abd = Abdominal, Thora = Thoracic, Ortho = Orthopedic, Bx = Biopsy, EP =
Electrophysiology, PCI = Percutaneous coronary intervention, CABG = Coronary artery
bypass graft
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Baseline Characteristics of Temporary Interruption Participants
All Patients in Safety/OnTreatment Population
(n=14 236)

Characteristic

Patients With Temporary Interruption
All (n=4692)

Rivaroxaban (n=2165)

Warfarin (n=2527)

Age, y, median (25th, 75th percentiles)

73 (65, 78)

73 (66, 78)

73 (66, 78)

73 (66, 78)

Female, n (%)

5645 (39.7)

1714 (36.5)

765 (35.3)

949 (37.6)

28.2 (25.1, 32.0)

28.4 (25.4, 32.3)

28.6 (25.4, 32.4)

28.3 (25.4, 32.1)

Blood pressure, systolic, mm Hg, median
(25th, 75th percentiles)

130 (120, 140)

130 (120, 140)

130 (120, 140)

130 (120, 140)

Blood pressure, diastolic, mm Hg, median
(25th, 75th percentiles)

80 (70, 85)

80 (70, 85)

80 (70, 85)

80 (70, 85)

590 (399, 807)

674 (473, 864)

677 (477, 868)

673 (467, 857)

11 525 (81.0)

3753 (80.0)

1740 (80.4)

2013 (79.7)

2511 (17.6)

879 (18.7)

397 (18.3)

482 (19.1)

200 (1.4)

60 (1.3)

28 (1.3)

32 (1.3)

Prior chronic aspirin, n (%)

5194 (36.5)

1727 (36.8)

814 (37.6)

913 (36.2)

Prior vitamin K antagonist, n (%)

8889 (62.4)

3030 (64.6)

1388 (64.1)

1642 (65.0)

CHADS2 score, mean (SD)

3.47 (0.94)

3.41 (0.95)

3.40 (0.95)

3.42 (0.96)

kg/m2,

BMI,
median (25th, 75th
percentiles)

Treatment exposure period, day, median
(25th, 75th percentiles)
Type of atrial fibrillation, n (%)
Persistent
Paroxysmal

NIH-PA Author Manuscript

Newly diagnosed or new onset

1

3 (<0.1)

2 (<0.1)

0 (0.0)

2 (0.1)

2

1855 (13.0)

740 (15.8)

344 (15.9)

396 (15.7)

3

6203 (43.6)

2029 (43.2)

942 (43.5)

1087 (43.0)

4

4085 (28.7)

1280 (27.3)

595 (27.5)

685 (27.1)

5

1809 (12.7)

549 (11.7)

243 (11.2)

306 (12.1)

6

281 (2.0)

92 (2.0)

41 (1.9)

51 (2.0)

History of stroke, TIA, embolism, n (%)

7794 (54.7)

2358 (50.2)

1077 (49.7)

1281 (50.7)

History of CHF, n (%)

8894 (62.5)

2926 (62.4)

1344 (62.1)

1582 (62.6)

History of hypertension, n (%)

12 887 (90.5)

4273 (91.1)

1959 (90.5)

2314 (91.6)

History of diabetes mellitus, n (%)

5683 (39.9)

1955 (41.7)

926 (42.8)

1029 (40.7)

History of myocardial infarction, n (%)

2460 (17.3)

874 (18.6)

375 (17.3)

499 (19.7)

836 (5.9)

303 (6.5)

131 (6.1)

172 (6.8)

Peripheral vascular disease, n (%)

NIH-PA Author Manuscript

COPD, n (%)

1493 (10.5)

573 (12.2)

250 (11.5)

323 (12.8)

Creatinine clearance (Cockcroft-Gault
equation), mL/min, median (25th, 75th
percentiles)

67 (52, 87)

68 (53, 88)

68 (54, 89)

67 (52, 86)

Temporary interruptions, median (25th,
75th percentiles)

0 (0, 1)

1 (1,2)

1 (1,2)

1 (1,2)

0

9544 (67.0)

1

2958 (20.8)

2958 (63.0)

1399 (64.6)

1559 (61.7)

2

1118 (7.9)

1118 (23.8)

517 (23.9)

601 (23.8)

3

347 (2.4)

347 (7.4)

150 (6.9)

197 (7.8)

4

153 (1.1)

153 (3.3)

54 (2.5)

99 (3.9)

5

54 (0.4)

54 (1.2)

19 (0.9)

35 (1.4)

Circulation. Author manuscript; available in PMC 2014 November 06.

Sherwood et al.

Characteristic

NIH-PA Author Manuscript

6–18

Page 16

All Patients in Safety/OnTreatment Population
(n=14 236)

Patients With Temporary Interruption
All (n=4692)

Rivaroxaban (n=2165)

Warfarin (n=2527)

62 (0.4)

62 (1.3)

26 (1.2)

36 (1.4)

BMI indicates body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; and TIA, transient ischemic attack.
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Characteristics of TIs

All TIs (n=7555)

TIs Among RivaroxabanTreated Patients (n=3393)

TIs Among WarfarinTreated Patients
(n=4162)

5 (4, 9)

6 (4, 10)

5 (4, 9)

35 (33, 38)

35 (33, 39)

35 (33, 38)

Surgical/invasive procedure

2997 (39.7)

1309 (38.6)

1688 (40.6)

Adverse event: nonbleeding

1874 (24.8)

816 (24.0)

1058 (25.4)

Subject error

1366 (18.1)

624 (18.4)

742 (17.8)

Adverse event: bleeding

995 (13.2)

540 (15.9)

455 (10.9)

Logistic difficulty

449 (5.9)

163 (4.8)

286 (6.9)

Site error

48 (0.6)

22 (0.6)

26 (0.6)

Characteristic
Duration of interruption, d, median (25th, 75th
percentiles)
Duration of risk period for events, d, median (25th, 75th
percentiles)
Reason for interruption,* n (%)

Reason unknown
TIs with bridging therapy

NIH-PA Author Manuscript

23 (0.3)

3 (0.1)

20 (0.5)

n=483 (6.4)

n=277 (8.2)

n=206 (4.9)

7 (1.4)

6 (2.2)

1 (0.5)

476 (98.6)

271 (97.8)

205 (99.5)

6 (4, 9)

6 (4, 10)

6 (4, 8)

Type of bridging therapy, n (%)
Fondaparinux
LMWH
Duration of bridging therapy, d, median (25th, 75th
percentiles)

LMWH indicates low-molecular-weight heparin; and TI, temporary interruption.

*

More than 1 reason could be provided for each TI.
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Population Characteristics of Participants Who Underwent Bridging
Bridging Therapy at Least Once
Characteristic

Yes (n=431)

No (n=4261)

P Value

Age, y, median (25th, 75th percentiles)

74 (68, 78)

73 (65, 78)

0.019

Female, n (%)

140 (32.5)

1574 (36.9)

0.067

kg/m2,

28.8 (26.0, 32.1)

28.4 (25.4, 32.3)

0.22

Blood pressure, systolic, mm Hg, median (25th, 75th percentiles)

130 (120, 140)

130 (120, 140)

0.81

Blood pressure, diastolic, mm Hg, median (25th, 75th percentiles)

80 (70, 85)

80 (70, 85)

0.91

BMI,

median (25th, 75th percentiles)

Type of atrial fibrillation, n (%)

0.44

Persistent

338 (78.4)

3415 (80.1)

Paroxysmal

85 (19.7)

794 (18.6)

Newly diagnosed or new onset

8 (1.9)

52 (1.2)

124 (28.8)

1603 (37.6)

0.0003

Prior vitamin K antagonist, n (%)

340 (78.9)

2690 (63.1)

<0.0001

CHADS2 score, mean (SD)

3.52 (0.93)

3.40 (0.96)

0.0094

0 (0.0)

2 (<0.1)

Prior chronic aspirin, n (%)

NIH-PA Author Manuscript

1
2

41 (9.5)

699 (16.4)

3

203 (47.1)

1826 (42.9)

4

117 (27.1)

1163 (27.3)

5

60 (13.9)

489 (11.5)

10 (2.3)

82 (1.9)

History of stroke, TIA, embolism, n (%)

6

226 (52.4)

2132 (50.0)

0.34

History of CHF, n (%)

261 (60.6)

2665 (62.5)

0.42

History of hypertension, n (%)

390 (90.5)

3883 (91.1)

0.66

History of diabetes mellitus, n (%)

207 (48.0)

1748 (41.0)

0.0049

History of myocardial infarction, n (%)

73 (16.9)

801 (18.8)

0.34

Peripheral vascular disease, n (%)

44 (10.2)

259 (6.1)

0.0009

COPD, n (%)

51 (11.8)

522 (12.3)

0.80

67 (53, 84)

68 (53, 88)

0.74

1 (1, 2)

1 (1, 2)

<0.0001

1

224 (52.0)

2734 (64.2)

2

125 (29.0)

993 (23.3)

3

59 (13.7)

288 (6.8)

4

15 (3.5)

138 (3.2)

5

4 (0.9)

50 (1.2)

6–18

4 (0.9)

58 (1.4)

Creatinine (Cockcroft-Gault equation), mL/min, median (25th, 75th percentiles)
Temporary interruptions, median (25th, 75th percentiles)

NIH-PA Author Manuscript

BMI indicates body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; and TIA, transient ischemic attack.
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Major bleeding

0.99

3.33

0.66

0.28

0.17

0.30

Event Rate per 30 d, %

37

111

46

18

9

20

No. of Events

0.79

3.00

0.95

0.37

0.18

0.41

Event Rate per 30 d %

Warfarin (n=2527 Patients, 4162 TIs)

1.26 (0.80, 2.00)

1.12 (0.85, 1.47)

0.70 (0.43, 1.13)

0.75 (0.36, 1.59)

0.93 (0.34, 2.56)

0.74 (0.36, 1.50)

HR (CI) for Rivaroxaban vs Warfarin

0.32

0.43

0.14

0.46

0.89

0.40

P Value

Stroke/systemic embolism/MI/death as a composite does not include multiple events in the same patient. CI indicates confidence interval; HR, hazard ratio; MI, myocardial infarction; NMCR, nonmajor
clinically relevant; and TI, temporary interruption.

95

Major/NMCR bleeding

11

MI
26

7

Stroke/systemic embolism/MI/death

12

Death

No. of Events

Stroke/systemic embolism

Events

Rivaroxaban (n=2165 Patients, 3393 TIs)

NIH-PA Author Manuscript
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14

Major bleeding

0.99

3.03

0.55

0.27

0.07

0.27

Event Rate per 30 d, %

18

42

14

3

3

8

No. of Events

0.97

2.69

0.73

0.16

0.16

0.42

Event Rate per 30 d, %

Warfarin (n=1162 Patients, 1683 TIs)

1.02 (0.50, 2.06)

1.13 (0.72, 1.78)

0.75 (0.31, 1.77)

1.70 (0.39, 7.44)

0.44 (0.05, 4.25)

0.65 (0.20, 2.13)

HR (CI) for Rivaroxaban vs Warfarin

0.96

0.59

0.51

0.48

0.48

0.48

P Value

Stroke/systemic embolism/MI/death as a composite does not include multiple events in the same patient. CI indicates confidence interval; HR, hazard ratio; MI, myocardial infarction, NMCR, nonmajor
clinically relevant; and TI, temporary interruption.

34

Major/NMCR bleeding

4

MI
8

1

Stroke/systemic embolism/MI/death

4

Death

No. of Events

Stroke/systemic embolism

Events

Rivaroxaban (n=968 Patients, 1297 TIs)

Outcomes During TIs for Only Surgical/Invasive Procedures Without Adverse Event Bleeding
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23
105

1 d prior

2 d prior
13

0

1

0

Major Bleeds

24

5

1

0

Major/ NMCR Bleeds

1316

57

19

24

n

16

0

0

0

Major Bleeds

37

1

1

0

Major/ NMCR Bleeds

Warfarin (n=1416 TIs)

This table contains all TIs for which “surgical/invasive procedure” is the only reason for interruption and for which the procedure date is known (n=2547). NMCR indicates nonmajor clinically relevant; and
TI, temporary interruption.

983

20

Same day

≥3 d prior

n

Time of Last Study Drug Dose Relative to Procedure

Rivaroxaban (n=1131 TIs)

Risk of Major and NMCR Bleeding by Timing of Preprocedure Study Drug Discontinuation
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Outcomes During TIs With and Without Bridging Therapy
Bridging Therapy (n=483 TIs)
Events

No. of Events

Event Rate per 30 d, %

No Bridging Therapy (n=7072 TIs)
No. of Events

Event Rate per 30 d, %

Stroke/systemic embolism

1

0.17

31

0.37

Death

2

0.33

14

0.17

MI

4

0.69

25

0.30

Stroke/systemic embolism/MI/death

5

0.86

67

0.82

22

4.83

184

3.02

5

0.91

69

0.88

Major/NMCR bleeding
Major bleeding

Stroke/systemic embolism/MI/death as a composite does not include multiple events in the same patient. MI indicates myocardial infarction;
NMCR, nonmajor clinically relevant; and TI, temporary interruption.
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